NanoString Releases Operating Results for Second Quarter of 2021
SEATTLE–(BUSINESS WIRE)– NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the second quarter ended June 30, 2021.
Second Quarter Financial Highlights
- Product and service revenue of $33.6 million, 59% year-over-year growth
- Instrument revenue of $11.8 million, 21% year-over-year growth. Instrument revenue includes $7.4 million of GeoMx® Digital Spatial Profiler (DSP) instrument revenue
- Consumables revenue of $18.0 million, 115% year-over-year growth. Consumables revenue includes $3.8 million GeoMx DSP consumables revenue
- Service revenue of $3.8 million, 29% year-over-year growth
- Cash, cash equivalents and short-term investments of $398.0 million at June 30, 2021
“The momentum behind our spatial biology franchise continues to increase with each quarter. We generated record orders for GeoMx DSP systems in the second quarter and the launch of our Whole Transcriptome Atlases have driven a steady increase in GeoMx consumable pull-through. Our Spatial Molecular Imager has been garnering strong interest from a diverse set of researchers, including both existing GeoMx users and single cell researchers who are just beginning to embrace spatial biology,” said Brad Gray, president & CEO of NanoString. “Meanwhile, our nCounter franchise achieved a major milestone with our one thousandth instrument placement and we’re proud of the continued scientific contribution from nCounter, with customers generating more than 300 new peer-reviewed publications in the second quarter.”
GeoMx DSP
- GeoMx Installed Base: Grew installed baseto approximately 190 GeoMx DSP Systems at June 30, 2021, as compared to approximately 65 at June 30, 2020
- GeoMx Mouse Whole Transcriptome Atlas: Began commercial shipments of the GeoMx Mouse Whole Transcriptome Atlas in the second quarter, which provides high throughput RNA profiling in the primary model organism for discovery research
- GeoMx Technology Access Program (TAP): Generated approximately 90 new GeoMx TAP orders in the second quarter, of which over 70% utilized GeoMx Whole Transcriptome Atlas products
- GeoMx Publications: Increased cumulative peer-reviewed publications to approximately 60 as of June 30, 2021, with approximately 10 new publications during the quarter
nCounter
- nCounter Installed Base: Grew installed base to approximately 1,015 nCounter® Analysis Systems at June 30, 2021, as compared to approximately 890 systems at June 30, 2020
- nCounter Publications: Surpassed 4,600 cumulative peer-reviewed publications utilizing nCounter technology at June 30, 2021
- Stem Cell Characterization Panel Launch: Launched the nCounter Stem Cell Characterization Panel for the analysis and optimization of stem cell lines used in the development of potential novel therapeutics
- Parker Institute for Cancer Immunotherapy Collaboration: Announced a collaboration with Parker Institute for Cancer Immunotherapy, which will utilize nCounter technology to characterize cellular therapy regimens that may improve patient outcomes across all cancer types
2021 Outlook
The company updated its revenue outlook for 2021, with results expected as follows:
- GeoMx DSP revenue of $48 to $50 million, as compared to previous guidance of $45 to $50 million, based on strong consumable utilization at NGS-enabled sites
- nCounter revenue, inclusive of all service revenue, of $95 to $97 million, as compared to previous guidance of $95 to $100 million, reflecting strong demand in North America partially offset by a slower pace of pandemic recovery in EMEA and APAC
- Total product and service revenue of $143 to $147 million, as compared to previous guidance of $140 to $150 million
The company reiterated its full-year outlook on gross margin, operating expenses and adjusted EBITDA.
Second Quarter Financial Results
We have elected to present selected non-GAAP, or adjusted, financial measures, including Adjusted EBITDA. These adjusted financial measures are calculated excluding certain items that may make it more challenging to compare our GAAP operating results across periods. Such items may include collaboration revenue, stock-based compensation, depreciation and amortization, or one-time charges such as transaction related fees and expenses or restructuring charges and severance costs. A reconciliation of adjusted financial measures to the nearest comparable GAAP financial measure can be found in the notes and table at the end of this press release.
(dollars in thousands) |
Three Months Ended June 30, |
||||||||||||||
|
GAAP |
|
Non-GAAP Adjusted |
||||||||||||
|
2021 |
|
2020 |
|
2021 |
|
2020 |
||||||||
Product and service revenue |
$ |
33,632 |
|
|
$ |
21,144 |
|
|
$ |
33,632 |
|
|
$ |
21,144 |
|
Collaboration revenue |
231 |
|
|
1,460 |
|
|
— |
|
|
— |
|
||||
Total revenue |
33,863 |
|
|
22,604 |
|
|
33,632 |
|
|
21,144 |
|
||||
Cost of product and service revenue |
15,481 |
|
|
10,712 |
|
|
14,735 |
|
|
10,082 |
|
||||
Research and development |
17,162 |
|
|
15,739 |
|
|
14,469 |
|
|
13,663 |
|
||||
Selling, general and administrative |
26,855 |
|
|
19,912 |
|
|
21,717 |
|
|
17,066 |
|
||||
Adjusted EBITDA |
N / A |
|
N / A |
|
$ |
(17,289) |
|
|
$ |
(19,667) |
|
||||
|
|
|
|
|
|
|
|
||||||||
Non-operating expense, net |
(1,385) |
|
|
(3,374) |
|
|
(1,385) |
|
|
(3,374) |
|
||||
Net loss |
$ |
(27,020) |
|
|
$ |
(27,133) |
|
|
$ |
(18,674) |
|
|
$ |
(23,041) |
|
|
|
|
|
|
|
|
|
||||||||
|
Six Months Ended June 30, |
||||||||||||||
|
GAAP |
|
Non-GAAP Adjusted |
||||||||||||
|
2021 |
|
2020 |
|
2021 |
|
2020 |
||||||||
Product and service revenue |
$ |
65,026 |
|
|
$ |
45,640 |
|
|
$ |
65,026 |
|
|
$ |
45,640 |
|
Collaboration revenue |
454 |
|
|
3,569 |
|
|
— |
|
|
— |
|
||||
Total revenue |
65,480 |
|
|
49,209 |
|
|
65,026 |
|
|
45,640 |
|
||||
Cost of product and service revenue |
31,104 |
|
|
21,729 |
|
|
29,762 |
|
|
20,670 |
|
||||
Research and development |
32,225 |
|
|
33,241 |
|
|
27,042 |
|
|
28,502 |
|
||||
Selling, general and administrative |
53,654 |
|
|
45,633 |
|
|
42,675 |
|
|
39,534 |
|
||||
Adjusted EBITDA |
N / A |
|
N / A |
|
$ |
(34,453) |
|
|
$ |
(43,066) |
|
||||
|
|
|
|
|
|
|
|
||||||||
Non-operating expense, net |
(3,229) |
|
|
(14,363) |
|
|
(3,229) |
|
|
(7,220) |
|
||||
Net loss |
$ |
(54,732) |
|
|
$ |
(65,757) |
|
|
$ |
(37,682) |
|
|
$ |
(50,286) |
|
|
|
|
|
|
|
|
|
Supplemental Information
As a supplement to the table above, we have posted to the investor relations section of our website, at www.nanostring.com, supplemental financial data that includes our adjusted financial measures as compared to the nearest comparable GAAP financial measures, for the second quarter and the six months ended June 30, 2021 and for each quarter of and the full year of 2020.
Conference Call
Management will host a conference call today beginning at 1:30 pm PT / 4:30 pm ET to discuss these results and answer questions. Investors and other interested parties can register for the call in advance by visiting http://www.directeventreg.com/registration/event/3414117. After registering, an email confirmation will be sent, including dial-in details and unique conference call codes for entry. Registration is open throughout the call, but to ensure connection for the full call, registration in advance is recommended. The link to the webcast and audio replay will be made available at the Investor Relations website: www.nanostring.com. A replay of the call will be available beginning August 4, 2021 at 7:30pm ET through midnight ET on August 11, 2021. To access the replay, dial (800) 585-8367 or (416) 621-4642 and reference Conference ID: 3414117. The webcast will also be available on our website for one year following the completion of the call.
Non-GAAP, or Adjusted, Financial Information
We believe that the presentation of non-GAAP, or adjusted, financial information provides important supplemental information to management and investors regarding financial and business trends relating to our financial condition and results of operations. Reconciliation of adjusted financial measures to the most directly comparable financial result as determined in accordance with GAAP are included at the end of this press release following the accompanying financial data. A reconciliation of adjusted guidance measures to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty regarding certain expenses that may be incurred in the future. For further information regarding why we believe that these adjusted measures provide useful information to investors, the specific manner in which management uses these measures, and some of the limitations associated with the use of these measures, please refer to “Notes Regarding Non-GAAP Financial Information” at the end of this press release.
About NanoString Technologies, Inc.
NanoString Technologies is a leading provider of life science tools for discovery and translational research. Our nCounter® Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision. Our GeoMx® Digital Spatial Profiler enables highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types. Our technology platforms are designed to facilitate a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. For more information, please visit www.nanostring.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding expectations for demand for our products and growth in our business, future revenue growth, the impact of new products and expansion into new markets, the growth trajectory of our nCounter and GeoMx franchises, the anticipated launch of new products and technology, our estimated 2021 operating results and our anticipated GAAP and non-GAAP operating results. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; delays or denials of regulatory approvals or clearances for products or applications; the extent and duration of the impact of the COVID-19 pandemic and adverse conditions in the general domestic and global economic markets; the effects of ongoing litigation; the impact of competition; the impact of expanded sales, marketing, product development and clinical activities on operating expenses; delays or other unforeseen problems with respect to manufacturing and product development; as well as the other risks set forth in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. NanoString Technologies disclaims any obligation to update these forward-looking statements.
The NanoString logo, NanoString, NanoString Technologies, GeoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc., in the United States and/or other countries.
NANOSTRING TECHNOLOGIES, INC. |
|||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |
|||||||||||||||
(In thousands, except per share amounts) |
|||||||||||||||
(Unaudited) |
|||||||||||||||
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
|
2021 |
|
2020 |
|
2021 |
|
2020 |
||||||||
Revenue: |
|
|
|
|
|
|
|
||||||||
Instruments |
$ |
11,816 |
|
|
$ |
9,800 |
|
|
$ |
23,561 |
|
|
$ |
19,634 |
|
Consumables |
17,981 |
|
|
8,369 |
|
|
33,944 |
|
|
19,869 |
|
||||
Services |
3,835 |
|
|
2,975 |
|
|
7,521 |
|
|
6,137 |
|
||||
Total product and service revenue |
33,632 |
|
|
21,144 |
|
|
65,026 |
|
|
45,640 |
|
||||
Collaboration |
231 |
|
|
1,460 |
|
|
454 |
|
|
3,569 |
|
||||
Total revenue |
33,863 |
|
|
22,604 |
|
|
65,480 |
|
|
49,209 |
|
||||
Costs and expenses: |
|
|
|
|
|
|
|
||||||||
Cost of product and service revenue |
15,481 |
|
|
10,712 |
|
|
31,104 |
|
|
21,729 |
|
||||
Research and development |
17,162 |
|
|
15,739 |
|
|
32,225 |
|
|
33,241 |
|
||||
Selling, general and administrative |
26,855 |
|
|
19,912 |
|
|
53,654 |
|
|
45,633 |
|
||||
Total costs and expenses (a) (b) |